Navigation Links
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Date:9/21/2007

nsulin glargine, showed significant improvements in beta-cell function as measured by arginine and glucose induced C-peptide (a peptide associated with insulin production) secretion during a glucose clamp procedure (a technique used to assess insulin secretion)(2,3). Specifically, C-peptide secretion in response to arginine administration (which produces maximal beta-cell stimulation) was 146 percent greater after one year of treatment with exenatide when compared to insulin glargine (mean ratio relative to baseline for exenatide and insulin glargine + or -SEM: 3.19 + or - 0.24 vs. 1.31 + or - 0.07, respectively, p<0.0001). First phase glucose induced C-peptide secretion was 52 percent greater after one year of exenatide compared to insulin glargine therapy (mean ratio relative to baseline + or -SEM: 1.75 + or - 0.10 vs. 1.16 + or - 0.06, respectively, p<0.0001). Second phase C-peptide secretion increased 185 percent more with exenatide (mean ratio relative to baseline + or -SEM: 3.05 + or - 0.22) versus insulin glargine (1.08 + or - 0.05, p<0.0001).

The average HbA1c of randomized patients at the start of the trial was 7.5 + or - 0.1 percent. Treatment with exenatide resulted in blood sugar control (as measured by reductions in HbA1c) comparable to treatment with insulin glargine (-0.8 + or - 0.1 percent and -0.7 + or - 0.2 percent, respectively, a difference between groups that was not statistically significant).

On average, exenatide treatment also resulted in a reduction in body weight. At the start of the study, randomized patients had a mean weight of 91.4 + or - 1.6 kg (201.6 + or - 3.5 lb). Patients on exenatide lost an average of 3.6 + or - 0.6 kg (7.8 + or - 1.4 lb), while those receiving insulin glargine gained an average of 1.0 + or - 0.8 kg (2.2 + or - 1.8 lb). The total difference in weight between the exenatide and insulin glargine groups was 4.6 kg (10.0 lb).

"Previous exenatide studies have shown comparable glycemic improvements wh
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... 24, 2014 IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has accepted  ... Directors.  Mr. Finio has accepted a senior level finance ... of his acceptance of his new position, Mr. Finio ... Director for IGI Laboratories, Inc.  The effective date of ...
(Date:7/24/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... fiscal year 2014 financial results after the market close ... will follow on the same day at 4:30 p.m. ... hosted by Dan Myers , President and Chief ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2Alimera Sciences To Release Second Quarter 2014 Results 2
... in LDL-C when Treated with 300 mg/week ISIS 301012 ... for 13 Weeks, - Study Presented in Poster Session Today at DALM Symposium in New York ... City, - Isis Will Host a Conference ... at http://www.isispharm.com , ...
... today,announced that the company has been awarded a ... and Technology (NIST) to develop a Sensor,System on ... markers in,a single assay. Successful development of ... of multifactorial conditions such as autoimmune disease and,allergy, ...
Cached Medicine Technology:Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 2Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 3Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 4Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 5Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients 6Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 2Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 3Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 4
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July ... don,t view their kids as unhealthy or recognize the health ... study. The children of the families surveyed for the ... Children,s Hospital in Providence, R.I. "A third categorized their ... Dr. Kyung Rhee, now an assistant professor of pediatrics at ...
(Date:7/24/2014)... of overweight and obese preschoolers works better when treatment ... the child is targeted, according to research published this ... University at Buffalo and Women and Children,s Hospital of ... obese and had one parent who participated in the ... body mass index (BMI) measurements, calculated based on height ...
(Date:7/24/2014)... When a foreign material like a medical device or ... body always responds. According to Northwestern University,s Guillermo Ameer, ... and affect the device,s function. , "You will always ... professor of biomedical engineering in Northwestern,s McCormick School of ... the Feinberg School of Medicine. "A problem with commonly ...
(Date:7/24/2014)... 2014 Horizon BCBSNJ’s second annual “Back ... family a rent-free week in a beautiful Lavallette shore ... Don’t miss your chance to win a week’s vacation ... all New Jersey residents, 25 or older.* Residents can ... http://www.facebook.com/HorizonBCBSNJ . , “A family vacation at the ...
(Date:7/24/2014)... Members of the Iowa State Board of Health ... of Sales at OutcomesMTM, as their Chairperson. Wolnerman said he ... and that his peers chose to keep him in this ... I can for the citizens of Iowa,” Wolnerman said. “As ... a special insight to concerns and issues related to the ...
Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Antioxidant biomaterial promotes healing 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... celebrating his one Year Anniversary as a Non-Smoker 60 Pounds Lighter. What ... quit smoking or lose 60 pounds but to do both within one year ... was able to turn his life around and improve his quality of life; ... , ...
... voice preference on two California reorganization plans , ... members began casting ballots this week in an advisory vote ... register their preferences on whether they want to be part ... a new statewide local representing a broader classification of healthcare ...
... County Health Director, Dr. Bob England Encourage all Families to ... One Middle School , , ... that Arizona has its first lab-confirmed case of influenza in ... Public Health, the Arizona Department of Health Services, the Arizona ...
... announced today the Company will hold an,investor conference call to discuss current business conditions ... is,(866) 901-2585. The international call in number is (404) 835-7099. , , ... & ... ctrego@minrad.com , ...
... Consulting Inc.,announces the addition of two new areas of ... engineering and technology,services. The company is also launching its ... The company has realigned its services into ... sustainability. , "We ...
... useful, studies find , , WEDNESDAY, Nov. 19 (HealthDay News) -- ... diabetes was no better at predicting a person,s risk for ... , The news is both encouraging and discouraging. , "The ... risk," said Dr. James Meigs, lead author of one of ...
Cached Medicine News:Health News:Former Smoker Celebrates One Year Anniversary of Being a Non-Smoker 60 Pounds Lighter 2Health News:Former Smoker Celebrates One Year Anniversary of Being a Non-Smoker 60 Pounds Lighter 3Health News:Advisory Vote Begins on California Long-Term Care Local 2Health News:American Lung Association of Arizona, Phoenix Fire and Maricopa County Public Health Urge Residents to Get Vaccinated Against the Flu 2Health News:American Lung Association of Arizona, Phoenix Fire and Maricopa County Public Health Urge Residents to Get Vaccinated Against the Flu 3Health News:American Lung Association of Arizona, Phoenix Fire and Maricopa County Public Health Urge Residents to Get Vaccinated Against the Flu 4Health News:Environmental and Technology Firm Integral Consulting Inc. Expands Services, Launches New Website 2Health News:Genetic Testing No Real Help in Predicting Type 2 Diabetes 2Health News:Genetic Testing No Real Help in Predicting Type 2 Diabetes 3
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
... is an Auto Refractor/Keratometer with ... refinement. Electronic elevation, automatic alignment, ... accuracy and all the other ... Marco Automatic Refractors/Keratometer famous, make ...
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Medicine Products: